Compare INMD & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INMD | PCRX |
|---|---|---|
| Founded | 2008 | 2006 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 842.0M | 1.0B |
| IPO Year | 2018 | 2010 |
| Metric | INMD | PCRX |
|---|---|---|
| Price | $13.58 | $23.24 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $16.75 | ★ $37.60 |
| AVG Volume (30 Days) | ★ 818.6K | 740.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 107.44 |
| EPS | N/A | ★ 0.16 |
| Revenue | N/A | ★ $541,533,000.00 |
| Revenue This Year | $1.70 | $9.77 |
| Revenue Next Year | $3.99 | $9.71 |
| P/E Ratio | ★ $10.11 | $147.31 |
| Revenue Growth | N/A | ★ 26.04 |
| 52 Week Low | $12.72 | $18.80 |
| 52 Week High | $19.09 | $27.99 |
| Indicator | INMD | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.21 | 55.05 |
| Support Level | $13.28 | $23.10 |
| Resistance Level | $14.80 | $23.82 |
| Average True Range (ATR) | 0.28 | 1.06 |
| MACD | -0.05 | 0.08 |
| Stochastic Oscillator | 58.85 | 77.96 |
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF, and Morpheus8, among others. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia, Israel, and other regions.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.